You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR LEVEMIR FLEXPEN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LEVEMIR FLEXPEN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00655200 ↗ Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus Completed Novo Nordisk A/S 2008-02-01 This study is conducted in Asia. The aim of this observational study is to evaluate the safety and tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the treatment of Filipino patients with Type 1 and Type 2 Diabetes Mellitus.
NCT00670683 ↗ Observational Study of Patients With Diabetes Using Levemir® FlexPen® Completed Novo Nordisk A/S 2007-07-01 This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea. The aim of this observational study is to evaluate the short term and the long term safety and efficacy of Levemir® FlexPen®. The study is planned and conducted as per requirement from Korea Food and Drug Administration (KFDA).
NCT00906529 ↗ Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin Withdrawn Novo Nordisk A/S Phase 4 2009-05-01 The purpose of this study is to determine whether aggressive (goal pre-prandial blood glucose <110 mg/dl) versus conservative (goal pre-prandial blood glucose <180mg/dl) diabetes treatment of type 2 diabetic patients on the general medical wards has any effect on hospital outcomes.
NCT00906529 ↗ Aggressive Versus Conservative Blood Glucose Control in Hospitalized Type 2 Diabetic Patients Using Detemir and Aspart Insulin Withdrawn University of Texas Southwestern Medical Center Phase 4 2009-05-01 The purpose of this study is to determine whether aggressive (goal pre-prandial blood glucose <110 mg/dl) versus conservative (goal pre-prandial blood glucose <180mg/dl) diabetes treatment of type 2 diabetic patients on the general medical wards has any effect on hospital outcomes.
NCT01420692 ↗ The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes Completed Hacettepe University N/A 2010-06-01 The main purpose of this study is to analyze the effects of the addition of sulfonylurea (gliclazide MR) or ,alternatively, basal insulin (insulin detemir) to life-style modification and metformin treatment as a second step treatment in type 2 diabetes mellitus on endothelial cell functions. The second goal is to identify the effects of these treatment alternatives on body-mass index, the changes in body fat mass, insulin resistance and on the insulin secretion capacity of beta cells. The third aim of this study is to determine the success rates of these treatment alternatives on glycemic control at 6 months follow-up.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LEVEMIR FLEXPEN

Condition Name

Condition Name for LEVEMIR FLEXPEN
Intervention Trials
Diabetes 3
Diabetes Mellitus, Type 2 3
Diabetes Mellitus, Type 1 2
Type 2 Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LEVEMIR FLEXPEN
Intervention Trials
Diabetes Mellitus, Type 2 5
Diabetes Mellitus 4
Diabetes Mellitus, Type 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LEVEMIR FLEXPEN

Trials by Country

Trials by Country for LEVEMIR FLEXPEN
Location Trials
Philippines 1
Turkey 1
United States 1
Korea, Republic of 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LEVEMIR FLEXPEN
Location Trials
Texas 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LEVEMIR FLEXPEN

Clinical Trial Phase

Clinical Trial Phase for LEVEMIR FLEXPEN
Clinical Trial Phase Trials
Phase 4 1
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LEVEMIR FLEXPEN
Clinical Trial Phase Trials
Completed 4
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LEVEMIR FLEXPEN

Sponsor Name

Sponsor Name for LEVEMIR FLEXPEN
Sponsor Trials
Novo Nordisk A/S 4
University of Texas Southwestern Medical Center 1
Hacettepe University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LEVEMIR FLEXPEN
Sponsor Trials
Other 5
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.